FDA Proposes To Add Bemotrizinol As Sunscreen Active Ingredient

Core Viewpoint - The U.S. Food and Drug Administration (FDA) is advancing sunscreen innovation by proposing to add bemotrizinol as a permitted active ingredient for sunscreens, aiming to modernize regulations and expand consumer choices [1][3]. Group 1: FDA's Proposal and Benefits - Bemotrizinol offers protection against both ultraviolet A and B rays, has low skin absorption, and rarely causes irritation, making it a safe and effective option for adults and children aged 6 months and older [2]. - If finalized, bemotrizinol will be recognized as a generally safe and effective sunscreen ingredient, enhancing consumer options in the market [2]. Group 2: Regulatory Context - Sunscreen products can enter the market without an approved drug application if they meet specific monograph requirements, including permitted active ingredients and uses [4]. - The FDA can modify an over-the-counter (OTC) monograph through an administrative order, allowing drug companies to initiate the process by submitting an OTC Monograph Order Request [4]. Group 3: Importance of Sunscreen - The FDA emphasizes the importance of broad-spectrum sunscreens with SPF 15 or higher in preventing sunburn and reducing skin cancer risks when used correctly alongside other protective measures [5]. - The agency urges Americans to use sunscreen as part of a comprehensive sun protection strategy, highlighting the public health benefits associated with sunscreen use [5].